Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q4 2017 call → NOWe need to determine if management explains where the company's business is going by narrating what its counterparties are themselves doing and scaling. The question asks: does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company already supplies or serves, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort? We need to look at the transcript. Management (Lee Gibson and Julie Shamburger) discuss the company's outlook. They talk about the Diboll acquisition, integration, loan growth, securities portfolio, tax reform, efficiency ratio, etc. They mention economic conditions in markets they serve. They talk about loan pipeline, expected loan growth of 7% in 2018. They talk about Trust income doubling due to acquisition. They talk about cost containment. They do not seem to narrate specific counterparties' own growth trajectories. They mention "customers" generally, but not specific identifiable counterparties. They talk about the markets being healthy, but that's macro. They talk about the acquisition of Diboll, which is a merger, not a customer. They talk about the integration and conversion. They do not describe any specific customer, partner, or program that they supply and that is scaling. The forward account is based on their own actions (loan growth, cost containment, integration) and macro conditions (tax reform, market health). There is no narration of counterparties' own expansion. So answer NO. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.